tiprankstipranks
Blurbs

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicycle Therapeutics (BCYC), Turning Point Therapeutics (TPTX) and Globus Medical (GMED)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bicycle Therapeutics (BCYCResearch Report), Turning Point Therapeutics (TPTXResearch Report) and Globus Medical (GMEDResearch Report).

Bicycle Therapeutics (BCYC)

In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Bicycle Therapeutics, with a price target of $70.00. The company’s shares closed last Friday at $15.23, close to its 52-week low of $14.43.

According to TipRanks.com, Benjamin has 0 stars on 0-5 stars ranking scale with an average return of -11.5% and a 31.3% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Spectrum Pharmaceuticals, and Iovance Biotherapeutics.

Bicycle Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $60.00, representing a 285.4% upside. In a report issued on May 23, Piper Sandler also maintained a Buy rating on the stock with a $37.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Turning Point Therapeutics (TPTX)

In a report released today, Silvan Tuerkcan from JMP Securities maintained a Hold rating on Turning Point Therapeutics. The company’s shares closed last Friday at $74.59, close to its 52-week high of $83.06.

According to TipRanks.com, Tuerkcan is ranked 0 out of 5 stars with an average return of -6.6% and a 33.0% success rate. Tuerkcan covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Logicbio Therapeutics, and Intellia Therapeutics.

Currently, the analyst consensus on Turning Point Therapeutics is a Moderate Buy with an average price target of $81.80, a 10.9% upside from current levels. In a report issued on June 3, Wedbush also downgraded the stock to Hold with a $76.00 price target.

Globus Medical (GMED)

In a report released today, David Turkaly from JMP Securities reiterated a Hold rating on Globus Medical. The company’s shares closed last Friday at $63.53.

According to TipRanks.com, Turkaly is a 3-star analyst with an average return of 2.4% and a 44.8% success rate. Turkaly covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics.

Currently, the analyst consensus on Globus Medical is a Moderate Buy with an average price target of $73.17.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BCYC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed